Table 1.
Criteria used to define metabolically healthy obesity in investigations on its impact on chronic kidney disease
| Variable | Jung et al. (2015)22 | Hashimoto et al. (2015)20 | Chang et al. (2016)21 | Wang et al. (2022)23 |
|---|---|---|---|---|
| Metabolic component | ||||
| BP (mmHg) | ≥ 130/85 or treatment | ≥ 130/85 or treatment | ≥ 130/85 or treatment | Diagnosis of HTN |
| FPG (mg/dL) | ≥ 100 or treatment | ≥ 100 or treatment | ≥ 100 or treatment | Diagnosis of DM |
| TG (mg/dL) | ≥ 150 or treatment | ≥ 150 or treatment | ≥ 150 or treatment | ≥ 200 |
| HDL-C (mg/dL) | < 40 (M)/50 (F) | < 40 (M)/50 (F) | < 40 (M)/50 (F) | < 40 |
| HOMA-IR | - | - | ≥ 2.5 | - |
| Other | Diagnosis of dyslipidemia TC ≥ 240 mg/dL LDL-C ≥ 160 mg/dL |
|||
| Metabolic health criteria | < 2 of the above | < 2 of the above | None of the above | None of the above |
| Obesity component | ||||
| BMI (kg/m2) | ≥ 25 | ≥ 25 | ≥ 25 | ≥ 30 |
BP, blood pressure; HTN, hypertension; FPG, fasting plasma glucose; DM, diabetes mellitus; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of Insulin resistance; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index.